OCTAVE-DUO

OCTAVE-DUO is a multi-disease, randomised clinical trial to determine whether a re-boost vaccine strategy can induce an immune response in clinically vulnerable patients with proven inadequate response to SARS-CoV-2 vaccine.

Patients with solid cancer; lymphoid malignancies; immune-mediated rheumatic diseases; end stage kidney disease; chronic liver disease; inflammatory bowel disease on immune suppressive therapy; haematopoietic stem cell transplant; and primary immunodeficiency who have received two doses of SARS-CoV-2 vaccine but have proven inadequate response to SARS-CoV-2 vaccine attending specialist clinics across the UK will be recruited. 

OCTAVE-DUO is a collaborative research project involving academic partners from the Universities of Glasgow, Birmingham, Oxford, Imperial College London and the IMPACT network. The project is funded by UK Research and Innovation (UKRI). 

 

News & Publications

Journal publications

C Goodyear, A Patel, et al. Immunogenicity of SARSCoV2 third dose vaccine strategies in immunocompromised patients with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multi-centre, randomised, controlled phase III trial. The Lancet Rheumatology, 8-Apr-2024. DOI https://doi.org/10.1016/S2665-9913(24)00065-1.

Plain English (Lay) Results Summary

In the pipeline.

News releases

May 2024 - Third Covid vaccine dose improves defence for some clinically extremely vulnerable patients

 August 2021 (Trial launch) - Clinical trial to test third COVID-19 vaccine for people with weakened immune systems, Open Access Government (published online 25/08/2021)